

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 December 2024 (19.12.2024)



(10) International Publication Number
WO 2024/255810 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/423 (2006.01)
C07D 407/14 (2006.01) A61K 31/343 (2006.01)
C07D 413/14 (2006.01) A61P 7/00 (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/CN2024/099076

(22) International Filing Date:

13 June 2024 (13.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/100520

15 June 2023 (15.06.2023)

CN

(71) Applicant: **HANGZHOU GLUBIO PHARMACEUTICAL CO., LTD** [CN/CN]; Room 1-803, Heda Medical Valley Center, No. 291 Fucheng Road, Xiasha District, Qiantang New Area, Hangzhou, Zhejiang 310018 (CN).

(72) Inventors: **FU, Liqiang**; 73 Building, 887 Zu Chong Zhi Road, Pudong New Area, Shanghai 201210 (CN). **QI, Zude**; 73 Building, 887 Zu Chong Zhi Road, Pudong New Area, Shanghai 201210 (CN). **JIN, Xuemei**; 73 Building, 887 Zu Chong Zhi Road, Pudong New Area, Shanghai 201210 (CN). **CONTRERAS, Adrian**; 10239 Flanders Ct, Suite 101, San Diego, CA (US). **LU, Chin-Chun**; 10239 Flanders Ct, Suite 101, San Diego, CA (US). **XIA, Yifeng**; 10239 Flanders Ct, Suite 101, San Diego, CA (US). **LU, Gang**; 10239 Flanders Ct, Suite 101, San Diego, CA (US).

(74) Agent: **XU & PARTNERS, LLC**. et al.; Room 106, Building No.1, Universal High-Tech Plaza 958, Zhen Bei Road, Putuo District, Shanghai 200333 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF

(57) Abstract: The present disclosure relates to dihydropyrimidine-2, 4 (1H, 3H) -dione-containing polycyclic compounds, or pharmaceutically acceptable salts thereof, and compositions thereof which are effective to reduce or modulate widely interspaced zinc finger motifs (WIZ) protein expression levels and/or induce fetal hemoglobin (HbF) expression, and also relates to methods of their preparation and their use in treatment of subjects in need.

WO 2024/255810 A1